R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: Results of a phase II Sarcoma Alliance for research through Collaboration study

Journal of Clinical Oncology

Volumn 29, Issue 34, 2011, Pages 4541-4547

  Pappo, Alberto S ^a   Patel, Shreyaskumar R ^b   Crowley, John ^c   Reinke, Denise K ^d   Kuenkele, Klaus Peter ^f   Chawla, Sant P ^h   Toner, Guy C ^j   Maki, Robert G ^k   Meyers, Paul A ^k   Chugh, Rashmi ^e   Ganjoo, Kristen N ⁱ   Schuetze, Scott M ^e   Juergens, Heribert ^g   Leahy, Michael G ^l   Geoerger, Birgit ^m   Benjamin, Robert S ^b   Helman, Lee J ⁿ   Baker, Laurence H ^e  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c USA   (United States)

^d Sarcoma Alliance for Research Through Collaboration   (United States)

^e UNIVERSITY OF MICHIGAN   (United States)

^f ROCHE DIAGNOSTICS GMBH   (Germany)

^g UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^h Sarcoma Oncology   (United States)

ⁱ STANFORD UNIVERSITY   (United States)

^j PETER MACCALLUM CANCER CENTRE   (Australia)

^k MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^l CHRISTIE HOSPITAL   (United Kingdom)

^m INSTITUT GUSTAVE ROUSSY   (France)

ⁿ NATIONAL CANCER INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; R 1507; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; BONE TUMOR; CANCER SURVIVAL; CHILD; EWING SARCOMA; EWING SARCOMA FAMILY OF TUMOR; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD; PRIMARY TUMOR; PRIORITY JOURNAL; SCHOOL CHILD; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CHILD; DRUG ADMINISTRATION SCHEDULE; HUMANS; MIDDLE AGED; RECEPTOR, IGF TYPE 1; RECURRENCE; SARCOMA, EWING; TREATMENT OUTCOME;

EID: 83255163333     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.34.0000     Document Type: Article

References (23)

1. Balamuth NJ, Womer RB: Ewing's sarcoma. Lancet Oncol 11:184-192, 2010
2. Granowetter L, Womer R, Devidas M, et al: Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: A Children's Oncology Group Study. J Clin Oncol 27:2536-2541, 2009
3. Grier HE, Krailo MD, Tarbell NJ, et al: Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 348:694-701, 2003 (Pubitemid 36237038)
4. Ginsberg JP, Goodman P, Leisenring W, et al: Long-term survivors of childhood Ewing sarcoma: Report from the childhood cancer survivor study. J Natl Cancer Inst 102:1272-1283, 2010
5. Kim SY, Toretsky JA, Scher D, et al: The role of IGF-1R in pediatric malignancies. Oncologist 14:83-91, 2009
6. LeRoith D, Werner H, Beitner-Johnson D, et al: Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr Rev 16:143-163, 1995
7. Zhan S, Shapiro DN, Helman LJ: Loss of imprinting of IGF2 in Ewing's sarcoma. Oncogene 11:2503-2507, 1995 (Pubitemid 26023817)
8. Scotlandi K, Benini S, Nanni P, et al: Blockage of insulin-like growth factor-I receptor inhibits the growth of Ewing's sarcoma in athymic mice. Cancer Res 58:4127-4131, 1998 (Pubitemid 28440569)
9. Benini S, Manara MC, Baldini N, et al: Inhibition of insulin-like growth factor I receptor increases the antitumor activity of doxorubicin and vincristine against Ewing's sarcoma cells. Clin Cancer Res 7:1790-1797, 2001 (Pubitemid 32708650)
10. Tolcher AW, Sarantopoulos J, Patnaik A, et al: Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J Clin Oncol 27:5800-5807, 2009
11. Olmos D, Postel-Vinay S, Molife LR, et al: Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: A phase 1 expansion cohort study. Lancet Oncol 11:129-135, 2010
12. Kurzrock R, Patnaik A, Aisner J, et al: A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumors. Clin Cancer Res 16:2458-2465, 2010
13. Toretsky JA, Kalebic T, Blakesley V, et al: The insulin-like growth factor-I receptor is required for EWS/FLI-1 transformation of fibroblasts. J Biol Chem 272:30822-30827, 1997 (Pubitemid 27527522)
14. Kim SY, Wan X, Helman LJ: Targeting IGF-1R in the treatment of sarcomas: Past, present and future. Bull Cancer 96:E52-60, 2009
15. Kurmasheva RT, Houghton PJ: IGF-I mediated survival pathways in normal and malignant cells. Biochim Biophys Acta 1766:1-22, 2006 (Pubitemid 44175635)
16. Green SJ, Dahlberg S: Planned versus attained design in phase II clinical trials. Stat Med 11:853-862, 1992
17. Kaplan AL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
18. Cox DR: Regression models and life tables. J Royal Stat Soc Series B 34:187-202, 1972
19. Cao L, Yu Y, Darko I, et al: Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody. Cancer Res 68:8039-8048, 2008
20. Zha J, O'Brien C, Savage H, et al: Molecular predictors of response to a humanized anti-insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer. Mol Cancer Ther 8:2110-2121, 2009
21. Hendrickson AW, Haluska P: Resistance pathways relevant to insulin-like growth factor-1 receptor-targeted therapy. Curr Opin Investig Drugs 10: 1032-1040, 2009
22. Huang F, Greer A, Hurlburt W, et al: The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors. Cancer Res 69:161-170, 2009
23. Baselga J, Tripathy D, Mendelsohn J, et al: Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Semin Oncol 26:78-83, 1999 (4 suppl 12)